Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capivasertib - AstraZeneca

Next Previous
X
Search
Drug Profile

Capivasertib - AstraZeneca

Alternative Names: AZD 5363; Truqap

Latest Information Update: 16 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
  • Developer AstraZeneca
  • Class Antineoplastics; Piperidines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 negative breast cancer
  • Phase III Prostate cancer; Triple negative breast cancer
  • Phase II Breast cancer; Endometrial cancer; Gastric cancer; Meningioma; Non-Hodgkin's lymphoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Preclinical Diffuse large B cell lymphoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 26 Sep 2024 Phase-III clinical trials in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent, Inoperable/Unresectable) in China (PO) (NCT06635447)
  • 26 Jul 2024 Registered for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in European Union (PO)
  • 17 Jul 2024 Registered for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top